of stable patients is required. This will involve formal handover between treating medical specialists within the Ig system. (See Review section) Yes By which specialty Neurologist No By which specialty Diagnosis must be (if verified neurologist did not make original diagnosis) Exclusion No exclusion criteria required. Criteria The indication has been modified to better describe First-line treatment for CIDP with Treatment of CIDP for patients in whom walking is treatment initiated when progression compromised or trial is significant disability eligible patients. is rapid, or walking is compromised, or Clinical assessments for efficacy now distinguish there is significant functional impairment and disability, with disability considered to Relapse of CIDP Patients within 6 months of impairment. be the most valid endpoint. commencement of off Ig therapy A new indication was created to support re-entry of patients that relapse within 6 months of off ig treatment. First-line treatment for CIDP with Treatment of CIDP for patients in whom walking is The criteria for eligibility have been more clearly defined. treatment initiated when progression compromised or there is significant disability The Score has been selected as the single, most Criteria is rapid, or walking is compromised, or easily measurable, accessible and simple assessment to there is significant functional determine disability in adults. Adult or child (10 years or older) impairment. Patients will qualify for initial treatment when the level of demonstrating significant disability or Diagnosis of CIDP verified by a disability as defined by an INCAT disability score is compromised walking as objectively neurologist; greater than 1. measured by Inflammatory Neuropathy
of stable patients is required. This will involve formal handover between treating medical specialists within the Ig system. (See Review section) Diagnosis must be verified Yes By which specialty Neurologist (if neurologist did not make original diagnosis) No By which specialty Exclusion Criteria No exclusion criteria required. First-line treatment for CIDP with treatment initiated when progression is rapid, or walking is compromised, or there is significant functional impairment. Treatment of CIDP for patients in whom walking is compromised or is significant disability Relapse of CIDP Patients within 6 months of commencement of off Ig therapy The indication has been modified to better describe eligible patients. Clinical assessments for efficacy now distinguish impairment and disability, with disability considered to be the most valid endpoint. A new indication was created to support re-entry of patients that relapse within 6 months of trial off ig treatment. Criteria First-line treatment for CIDP with treatment initiated when progression is rapid, or walking is compromised, or there is significant functional impairment. Diagnosis of CIDP verified by a neurologist; Treatment of CIDP for patients in whom walking is compromised or there is significant disability Adult or child (10 years or older) demonstrating significant disability or compromised walking as objectively measured by Inflammatory Neuropathy The criteria for eligibility have been more clearly defined. The Score has been selected as the single, most easily measurable, accessible and simple assessment to determine disability in adults. Patients will qualify for initial treatment when the level of disability as defined by an INCAT disability score is greater than 1.
chronic-inflammatory-demyelinating-polyneuropathy%28cidp%29.DOCX